rhuMAb-VEGF: Phase II

DNA reported preliminary data from its 104-patient, open label study of rhuMAb-VEGF in combination with 5-fluorouracil (5-FU)/leucovorin, showing

Read the full 187 word article

How to gain access

Continue reading with a
two-week free trial.